top of page

Presidential Reception celebrating Female Entrepreneurship, Innovation, Creativity & Sustainable

DUBLIN, IRELAND – May 10, 2018 – Founder & Chief Scientific Officer of ATXA Therapeutics, Prof. Therese Kinsella, attended a reception with the President of Ireland Michael D. Higgins and his wife Sabina Higgins, at Áras an Uachtaráin on Friday, May 4th, 2018.

The reception was organised to celebrate Female Entrepreneurship, Innovation, Creativity and the Sustainable Economy, and aimed to encourage and highlight the achievements of women at the very highest levels in research and enterprise across Ireland.

Prof. Therese Kinsella with President Michael D. Higgins and his wife Sabina Higgins, at Áras an Uachtaráin.

During his speech, the President stressed how the event provided an uplifting reminder of the depth of the entrepreneurial talent that is developing and flourishing in Ireland.

"For the success of Ireland’s indigenous economy, the continued development of entrepreneurship is vital. I thank each and every one of you for your entrepreneurial spirit, your determination and your vision which have helped to not only build your own success stories, but are also contributing to Irish society. Your willingness to innovate, take chances and turn dreams into realities, are a greatly inspiring example of the qualities that are necessary in all areas of our shared lives if we are to craft, together, a future of hope and possibility."

For the full speech, and further details about the event, see

About ATXA Therapeutics

Headquartered in Dublin, Ireland, ATXA Therapeutics Limited is a spin-out company from University College Dublin whose primary focus is to advance clinical trials and to secure marketing authorization of novel therapies for the treatment of Pulmonary Arterial Hypertension (PAH), serving a previously unmet medical need by offering improved treatment options to the prescribing physician and new hope for the PAH patient. Founded in May 2015, ATXA Therapeutics Limited is the culmination of over 20 years of extensive research and over €15m of grant funding and a proven track record in understanding of the biology and signalling of the human prostanoid receptors in the cardiovascular disease and oncology setting. For more information, please visit

124 views0 comments
bottom of page